bifido

BUSINESS AREA

Pharmabiotics

Microbiome Challenge
Bifido Therapeutics

Bacterial
Therapeutics

Pharmaceutical role-playing probiotics

Although current definitions exclude these products from the ‘Probiotics’ category,
we propose that microbial-derived molecules with health benefits could be included
in a sub-category termed “Pharmabiotics” within probiotics.

PharmaceuticalProbioticsPharmabiotics+=

R&D
Platform

INTEGRATED PLATFORM

EXPRESS-PLATFORM

One-stop industrialization platform based on
microbiome research

PLATFORM
TECHNOLOGY

biMUN

Immunomodulatory technology based on
human microbiome analysis.

PLATFORM
TECHNOLOGY

biGEX

Cell factory and drug delivery system
based on engineered Bifidobacterium.

Clinical Trials
Conducting Now

Beyond the functionality of probiotics, its pharmaceutical role is drawing attention around the world. We are continuously conducting human research to prove the effects of the Pharmabiotics in collaboration with university hospitals.

  • BRAIN

    Improvement of cognitive function,
    memory and depression in the elderly

    Seoul National University

  • SKIN

    Decreased incidence of eczema in infants

    Samsung Hospital Pediatrics

  • GUT

    Combination therapy Improved treatment
    effect for ulcerative colitis

    Medical school of Palermo University Italy

  • KIDNEY

    Improving immunity and inflammation
    indicators in kidney dialysis patients

    Korea University Hospital Internal Medicine

  • JOINT

    Composition containing bifidobaccterium for
    alleviating, preventing of treating RA

    Catholic Hospital Internal Medicine

  • NOSE

    Improvement of nasal congestion
    and rhinitis symptoms

    Seoul National University Internal Medicine

Currently, Bifido Co,. Ltd is performing research for the development of the pharmaceutical Bifidobacterium strain suppressing rheumatoid arthritis (RA) in collaboration with Catholic Hospital RA Center.

Composition for improving, treating or preventing rheumatoid arthritis containing Bifidobacterium
(Korea Patent No.: 10-2074445)
Composition containing bifidobaccterium for alleviating, preventing of treating RA
(US Patent No.: US 10,617,725 B2)

SEE PIPELINE
top으로 이동